|
1
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hruban RH, Boffetta P, Hiraoka N,
Iacobuzio-Donahue C, Kato Y, Kern SE, Klimstra DS, Kloppel G,
Maitra A, Offerhaus GJA, et al: Ductal Adenocarcinoma of the
Pancreas. In: World Health Organization Classification of Tumours.
Pathology & GeneticsTumours of the Digestive System. Bosman FT,
Carneiro F, Hruban RH and Theise ND: IARC; Lyon: pp. 281–291.
2010
|
|
3
|
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo
M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P,
et al: DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J Clin
Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moor M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgon-Bourgade S, de
la Fouchardiére C, et al: FOLFILINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Groot VP, Rezaee N, Wu W, Cameron JL,
Fisgman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL and He J:
Patterns, timing, and predictors of recurrence following
pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. Mar
23–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yokoyama N, Otani T, Hashidate H, Maeda C,
Katada T, Sudo N, Manabe S, Ikeno Y, Tuyoda A and Katayanagi N:
Real-time detection of hepatic micrometastases from pancreatic
cancer by intraoperative fluorescence imaging: Preliminary results
of a prospective study. Cancer. 118:2813–2819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Satoi S, Yanagimoto H, Yamamoto T,
Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T,
Ryota H, et al: A clinical role of staging laparoscopy in patients
with radiographically defined locally advanced pancreatic ductal
adenocarcinoma. World J Surg Oncol. 14:142016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suemizu H, Monnai M, Ohnishi Y, Ito M,
Tamaoki N and Nakamura M: Identification of a key molecular
regulator of liver metastasis in human pancreatic carcinoma using a
novel quantitative model of metastasis in
NOD/SCID/γcnull (NOG) mice. Int J Oncol.
31:741–751. 2007.PubMed/NCBI
|
|
12
|
Furukawa D, Chijiwa T, Matsuyama M, Mukai
M, Matsuo EI, Nishimura O, Kawai K, Suemizu H, Hiraoka N, Nakagohri
T, et al: Zinc finger protein 185 is a liver metastasis-associated
factor in colon cancer patients. Mol Clin Oncol. 2:709–713.
2014.PubMed/NCBI
|
|
13
|
Zheng Q and Zhao Y: The diverse
biofunctions of LIM domain proteins: Determined by subcellular
localization and protein-protein interaction. Biol Cell.
99:489–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang JS, Gong A and Young CY: ZNF185, an
actin-cytoskeleton-associated growth inhibitory LIM protein in
prostate cancer. Oncogene. 26:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamada K, Monnai M, Kawai K, Nishime C,
Kito C, Miyazaki N, Ohnishi Y, Nakamura M and Suemizu H: Liver
metastasis models of colon cancer for evaluation of drug efficacy
using NOD/Shi-scid IL2Rγnull (NOG) mice. Int J Oncol.
32:153–159. 2008.PubMed/NCBI
|
|
16
|
Matsuyama M, Wakui M, Monnai M, Mizushima
T, Nishime C, Kawai K, Ohmura M, Suemizu H, Hishiki T, Suematsu M,
et al: Reduced CD73 expression and its association with altered
purine nucleotide metabolism in colorectal cancer cells robustly
causing liver metastases. Oncol Lett. 1:431–436. 2010.PubMed/NCBI
|
|
17
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. Wiley-Blackwell;
Hoboken, NJ: 2011
|
|
18
|
Japan-Pancreas-Society: Classification of
Pancreatic Cancer. Kanehara, Tokyo, Japan: 2011
|
|
19
|
Oguro S, Ino Y, Shimada K, Hatanaka Y,
Matsuno Y, Esaki M, Nara S, Kishi Y, Kosuge T and Hiraoka N:
Clinical significance of tumor-infiltrating immune cells focusing
on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci.
106:1750–1760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schaller MD: Paxillin: A focal
adhesion-associated adaptor protein. Oncogene. 20:6459–6472. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mierke CT: The role of vinculin in the
regulation of the mechanical properties of cells. Cell Biochem
Biophys. 53:115–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yam JW, Tse EY and Ng IO: Role and
significance of focal adhesion proteins in hepatocellular
carcinoma. J Gastroenterol Hepatol. 24:520–530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nagano M, Hoshino D, Koshikawa N, Akizawa
T and Seiki M: Turnover of focal adhesions and cancer cell
migration. Int J Cell Biol. 2012:3106162012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao CJ, Du SK, Dang XB and Gong M:
Expression of paxillin is correlated with clinical prognosis in
colorectal cancer patients. Med Sci Monit. 21:1989–1995. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi J, Wang S, Zhao E, Shi L, Xu X and
Fang M: Paxillin expression levels are correlated with clinical
stage and metastasis in salivary adenoid cystic carcinoma. J Oral
Pathol Med. 39:548–551. 2010.PubMed/NCBI
|
|
26
|
Li HG, Xie DR, Shen XM, Li HH, Zeng H and
Zeng YJ: Clinicopathological significance of expression of
paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World
J gastroenterol. 11:1445–1451. 2005. View Article : Google Scholar : PubMed/NCBI
|
